
|Videos|August 10, 2017
Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer
Author(s)Oliver Sartor, MD
Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.
Advertisement
Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.
Cellular studies are still needed to investigate the immune response caused by sipuleucel-T, explains Sartor.
Additionally, studies are needed to determine if immunotherapies are more active in different patient populations, states Sartor.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5



































